1 ANNEX I Communicable diseases and related special health issues subject to epidemiological surveillance, as referred to in Article 1, Regulation (EU) 2026/2097

In forcesince 18 Sep 2026

Anthrax

Arenavirus infection, excluding lymphocytic choriomeningitis

Botulism

Brucellosis

Campylobacteriosis

Chikungunya virus disease

Chlamydial infection, including Chlamydial lymphogranuloma (venereum) (LGV)

Cholera

Coronavirus disease 2019 (COVID-19)

Variant Creutzfeldt-Jakob disease

Crimean-Congo haemorrhagic fever

Dengue

Diphtheria

Echinococcosis

Filovirus infection

Gonococcal infection

Haemophilus influenzae infection, invasive disease

Hantavirus infection

Acute hepatitis A

Hepatitis B

Hepatitis C

Human immunodeficiency virus (HIV) infection and Acquired immunodeficiency syndrome (AIDS)

Influenza, seasonal

Influenza, zoonotic

Legionnaires’ disease

Leptospirosis

Listeriosis

Malaria

Measles

Meningococcal infection, invasive disease

Mpox

Mumps

Pertussis

Plague

Streptococcus pneumoniae infection, invasive disease

Acute poliomyelitis

Q fever

Rabies and other lyssavirus infections

Respiratory syncytial virus (RSV) infection

Rift Valley fever

Rubella

Congenital rubella syndrome

Salmonella enteritis

Shiga toxin-producing E. coli infection (STEC), including haemolytic-uraemic syndrome (HUS)

Shigellosis

Smallpox

Syphilis

Congenital syphilis

Tick-borne encephalitis, both Central European and Far Eastern

Congenital toxoplasmosis

Trichinellosis

Tuberculosis

Tularaemia

West Nile virus infection

Yellow fever

Yersiniosis, intestinal

Zika virus disease

Antimicrobial resistance (including antimicrobial consumption)

Healthcare-associated infections